Repligen Corporation $RGEN Stock: Riverbridge Partners LLC Decreases Holdings

by · The Markets Daily

Riverbridge Partners LLC cut its stake in Repligen Corporation (NASDAQ:RGEN – Free Report) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,046 shares of the biotechnology company’s stock after selling 6,461 shares during the quarter. Riverbridge Partners LLC owned approximately 0.26% of Repligen worth $31,919,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. New York Life Investment Management LLC boosted its holdings in shares of Repligen by 9.1% during the third quarter. New York Life Investment Management LLC now owns 7,868 shares of the biotechnology company’s stock worth $1,512,000 after acquiring an additional 659 shares during the period. AlphaCore Capital LLC grew its position in shares of Repligen by 90.4% in the third quarter. AlphaCore Capital LLC now owns 3,930 shares of the biotechnology company’s stock valued at $755,000 after purchasing an additional 1,866 shares during the last quarter. Retirement Systems of Alabama grew its position in shares of Repligen by 6.1% in the third quarter. Retirement Systems of Alabama now owns 58,210 shares of the biotechnology company’s stock valued at $11,190,000 after purchasing an additional 3,368 shares during the last quarter. Clear Wave Wealth Management LLC acquired a new position in shares of Repligen in the third quarter valued at approximately $218,000. Finally, Fulcrum Asset Management LLP bought a new position in shares of Repligen during the third quarter worth approximately $86,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $173.98 on Wednesday. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $198.87. The company’s 50 day moving average price is $177.26 and its two-hundred day moving average price is $145.58. The firm has a market cap of $11.12 billion, a PE ratio of 87.72, a PEG ratio of 3.07 and a beta of 1.11. The company has a quick ratio of 8.43, a current ratio of 9.88 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company had revenue of $209.31 million during the quarter, compared to the consensus estimate of $206.70 million. During the same period in the previous year, the business earned $0.46 earnings per share. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. Equities research analysts predict that Repligen Corporation will post 2.07 earnings per share for the current year.

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. JPMorgan Chase & Co. lifted their price target on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group upped their price objective on Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a report on Monday, October 19th. Weiss Ratings cut Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, November 2nd. UBS Group reiterated a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Finally, Barclays lifted their target price on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $178.57.

Get Our Latest Report on RGEN

Repligen Profile

(Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

Read More